Testosterone and Growth Hormone for Bone Loss in Men
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00080483 |
|
Recruitment Status :
Completed
First Posted : April 6, 2004
Results First Posted : June 13, 2014
Last Update Posted : June 13, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hypopituitarism Hypogonadism Growth Hormone Deficiency | Drug: Testosterone plus somatropin Drug: testosterone | Phase 2 |
Replacement of testosterone or growth hormone in patients who are deficient improves osteoporosis associated with these deficiencies. In some tissues, such as muscle, the effects of testosterone and growth hormone are additive, but it is not known if the effects are additive in bone as well. This study will compare the effects of testosterone alone with testosterone plus growth hormone in improving bone structure in men with total pituitary hormone deficiency.
Participants in this study will be men who have pituitary or hypothalamic disease and have deficiencies of all pituitary hormones, but who have not been treated with either testosterone or growth hormone. The men will be randomly assigned to receive either testosterone alone or testosterone plus growth hormone for two years. Testosterone in a gel form will be applied daily to the skin. Growth hormone will be self-administered by daily subcutaneous injection. Blood concentrations of both hormones will be monitored with blood tests every 3 months during the 2-year study. Doses of the hormones will be adjusted to keep blood concentrations of the hormones within the normal range. Changes in bone structure will be assessed noninvasively before treatment and after one year and two years of treatment by magnetic resonance microimaging (µMRI) and dual energy X-ray absorptiometry (DEXA).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 35 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Will Testosterone and Growth Hormone Improve Bone Structure? |
| Study Start Date : | March 2004 |
| Actual Primary Completion Date : | September 2010 |
| Actual Study Completion Date : | September 2010 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 1
Testosterone transdermally 5 g a day and somatropin subcutaneously 2 µg/kg body weight a day
|
Drug: Testosterone plus somatropin
AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years |
|
Active Comparator: 2
AndroGel transdermally 5 g a day for two years
|
Drug: testosterone
AndroGel transdermally 5 g a day for two years |
- MicroMRI-derived Structural (Bone Volume Fraction-BVF) of the Distal Tibia at Baseline and After One and Two Years of Treatment. [ Time Frame: baseline, one year, two years ]Increased bone volume fraction (the fraction of bone that is bone, as opposed to the fraction that is marrow), as determined by magnetic resonance of the distal tibia
- Increased Trabecular Thickness, as Determined by Magnetic Resonance of the Distal Tibia [ Time Frame: 2 years ]
- Improved Architectural Parameters of Trabecular Bone Reflecting Connectivity, as Determined by Magnetic Resonance Imaging [ Time Frame: 2 years ]
- Increased Cortical Thickness and Cortical Density, as Determined by Peripheral Quantitative Computed Tomography of the Tibial Metaphysis [ Time Frame: 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Documented hypothalamic or pituitary hormone deficiency
- Testosterone deficiency, defined as total serum testosterone less than 250 ng/dL at two 8 AM readings
- Growth hormone deficiency, defined by either of the following:
- For subjects who have thyroxine and cortisol deficiencies, either a subnormal age-specific IGF-1 or a peak GH response to arginine-GHRH of less than 4.1 ng/mL
- For subjects who do not have thyroxine and cortisol deficiencies, either a subnormal age-specific IGF-1 or a peak GH response to arginine-GHRH of less than 4.1 ng/mL
- Duration of testosterone and growth hormone deficiencies of two years or more
- Replacement of cortisol and/or thyroxine deficiencies
- Able to give informed consent
Exclusion Criteria:
- Current testosterone treatment or treatment during the two years prior to study entry
- Current growth hormone treatment or treatment during the three years prior to study entry
- Use of other prescription or over-the-counter androgens (androstenedione, DHEA), estrogens, or antiandrogens (spironolactone, ketoconazole)
- Diseases that could influence bone, such as hyperparathyroidism
- Medications that could influence bone, such as anticonvulsants or glucocorticoids (prednisone greater than 20 mg/day for longer than 2 weeks/year). Calcium and over-the-counter vitamin D supplements are allowed.
- Cancer that could limit life expectancy to fewer than 5 years
- Neuromuscular disease or history of stroke with residual neurological defect
- Severe or uncontrolled psychiatric illness or dementia
- Noncancerous enlargement of the prostate gland (American Urological Association symptom score greater than 21)
- Prostate cancer by history, prostate nodule on digital rectal exam (DRE), or prostate specific antigen (PSA) greater than 4
- Current alcohol or drug dependence
- Heart failure (New York class III or IV)
- Unstable angina
- Myocardial infarction within 3 months of study entry
- Liver disease (ALT greater than 3 x normal)
- Renal disease (serum creatinine greater than 2.5 mg/dl)
- Diabetes mellitus (glycosolated hemoglobin greater than 8.0%)
- Hypertension (systolic BP greater than 160 or diastolic BP greater than 100 mm Hg)
- Hematocrit greater than 48%
- Weight greater than 300 pounds
- Poor quality scan at baseline even when repeated
- Untreated, severe, obstructive sleep apnea (Epworth sleepiness score greater than 10)
- Unable to undergo an MRI because of a cardiac pacemaker or ferrometallic objects in the body
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00080483
| United States, Pennsylvania | |
| Hospital of the University of Pennsylvania | |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Principal Investigator: | Peter J. Snyder, MD | University of Pennsylvania | |
| Principal Investigator: | Cecilia Lansang, MD | University of Florida |
| Responsible Party: | Peter Snyder, Professor of Medicine, University of Pennsylvania |
| ClinicalTrials.gov Identifier: | NCT00080483 |
| Other Study ID Numbers: |
R01AR050618 ( U.S. NIH Grant/Contract ) R01AR050618 ( U.S. NIH Grant/Contract ) NIAMS-118 |
| First Posted: | April 6, 2004 Key Record Dates |
| Results First Posted: | June 13, 2014 |
| Last Update Posted: | June 13, 2014 |
| Last Verified: | December 2013 |
|
Hypopituitarism Hypogonadism Gonadal Disorders Endocrine System Diseases Pituitary Diseases Hypothalamic Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Methyltestosterone Testosterone |
Testosterone undecanoate Testosterone enanthate Testosterone 17 beta-cypionate Androgens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Anabolic Agents |